1527-3350/asset/cover.gif?v=1&s=3cd983af6575c8dbfd6b47a63ffa95415ace15f8 "Hepatology")
fax: 773-834-1288.
1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Viral Hepatitis
You have full text access to this OnlineOpen article
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy†‡§
Article first published online: 20 APR 2006
DOI: 10.1002/hep.21159
Copyright © 2006 American Association for the Study of Liver Diseases
Additional Information
How to Cite
Jensen, D. M., Morgan, T. R., Marcellin, P., Pockros, P. J., Reddy, K. R., Hadziyannis, S. J., Ferenci, P., Ackrill, A. M. and Willems, B. (2006), Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. Hepatology, 43: 954–960. doi: 10.1002/hep.21159
- †
Potential conflict of interest: Dr. Willems advises and received grants from Roche. Dr. Jensen is a consultant for and received grants from Roche. Dr. Reddy advises and is on the speakers' bureau for Roche. He also advises for Schering-Plough. Dr. Ferenci consults for, advises, is on the speakers' bureau for, and received grants from Roche. Dr. Morgan is on the speakers' bureau for and received grants from Roche and Schering-Plough. Prof. Hadziyannis consults for, advises, is on the speakers' bureau for, and received grants from Roche. He also received grants from Schering-Plough. Dr. Pockros is a consultant for Roche, and is on the speakers' bureau for and received grants from Roche and Schering-Plough. Dr. Marcellin advises, is on the speakers' bureau for, and received grants from Roche.
- ‡
This article has been corrected since its original publication. Please see Hepatology 2006;43:1410 for further details.
- §
See Editorial on Page 909
Publication History
- Issue published online: 20 APR 2006
- Article first published online: 20 APR 2006
- Manuscript Accepted: 10 FEB 2006
- Manuscript Received: 7 NOV 2005
Funded by
- Roche (Basel, Switzerland)
- Abstract
- Article
- References
- Cited By
Abstract
Approximately one third of hepatitis C virus (HCV) genotype 1 patients achieved a sustained virological response (SVR) after 24 weeks of treatment with peginterferon α-2a (40 kd) plus ribavirin in a randomized, multinational trial. We aimed to identify factors associated with a rapid virological response (RVR) at week 4 (HCV RNA <50 IU/mL) and a SVR (HCV RNA <50 IU/mL at the end of follow-up) in these patients. Stepwise multiple logistic regression analysis was used to explore the prognostic factors for a RVR and SVR in genotype 1 patients treated for 24 weeks. Fifty-one of 216 (24%) genotype 1 patients in the 24-week treatment groups had a RVR. SVR rates were considerably higher in patients with than without a RVR (89% vs. 19%, respectively). Patients with a baseline HCV RNA of less than 200,000 IU/mL (OR 9.7, 95% CI 4.2-22.5; P < .0001) or 200,000-600,000 IU/mL (OR 3.6, 95% CI 1.5-9.1; P = .0057) were more likely to achieve a RVR than those with HCV RNA greater than 600,000 IU/mL. HCV subtype (1b vs. 1a) was also independently associated with RVR (OR 1.8, 95% CI 0.9-3.7; P = .0954). RVR (OR 23.7 vs. no RVR, 95% CI 9.1-61.7) and baseline HCV RNA less than 200,000 IU/mL (OR 2.7 vs. >600,000 IU/mL, 95% CI 1.1-6.3; P < .026) were significant and independent predictors of SVR in patients treated for 24 weeks. In conclusion, patients infected with HCV genotype 1 and treated with peginterferon α-2a/ribavirin sustained a RVR 24% of the time. This portends an 89% probability of a SVR after 24 weeks of treatment. (HEPATOLOGY 2006;43:954–960.)